Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
June 25, 2025
General
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
SAN DIEGO—(BUSINESS WIRE)—Jun. 25, 2025—Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth.
Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts during 2025-2027—underscoring the breadth of its pipeline and the momentum behind its R&D strategy.
ANTICIPATED PIPELINE MILESTONES
Q3 2025 - Phase 2 study initiation for ACP-204 in Lewy Body Dementia Psychosis (LBDP)
Q3 2025 - Phase 3 study initiation in Japan for trofinetide in Rett syndrome
Early Q4 2025 - Topline results for the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi syndrome (PWS) following the recent completion of enrollment
Q4 2025 - Phase 2 study initiation for ACP-211 in major depressive disorder (MDD)
Q4 2025 - First in human study of ACP-271 in healthy volunteers
Q1 2026 - Potential approval from European Medicines Agency for trofinetide
Mid-2026 - Topline results from ACP-204 Phase 2 study in Alzheimer’s disease psychosis (ADP)
2026 - Phase 2 study initiation for ACP-711 in Essential Tremor (ET)
“Acadia is building from a position of strength, with two commercial franchises on track to deliver over $1 billion in net sales this year,” said Catherine Owen Adams, Chief Executive Officer. “As we advance our pipeline, the five molecules we showcase today represent a multibillion-dollar incremental revenue opportunity. They also underscore our unwavering commitment to bold science and our focus on delivering transformative therapies for patients with serious and underserved neurological and rare diseases. We believe the opportunity ahead is extraordinary—and we are confident in our ability to execute with discipline and purpose as we work to build a biotech powerhouse.”
“At Acadia, we’re building a strong, sustainable pipeline focused on progressing the most promising science with the goal of meaningfully improving patient care,” said Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of R&D. “Our pipeline is moving forward with real momentum. Between now and the end of 2026, we plan to initiate seven Phase 2 or 3 studies, with five key readouts anticipated by the end of 2027. We remain deeply committed to advancing care in neurological and rare diseases, leveraging our development expertise and commercial strength to bring meaningful innovation to patients.”
The Company will be discussing the following pipeline programs today:
ACP-101 (intranasal carbetocin)
A long-acting analogue of human oxytocin for the potential treatment of PWS
ACP-204
A new, highly selective, potent inverse agonist of 5-HT2A that builds upon lessons learned from pimavanserin for the potential treatment of ADP and LBDP
ACP-211
An orally administered, selectively deuterated form of R-Norketamine for the potential treatment of MDD
ACP-711
A selective **AA-α3 modulator targeting the potential treatment of ET
ACP-271
A GPR88 agonist for the potential treatment of Tardive Dyskinesia and Huntington’s Disease
To register for the live webcast, please click here. A replay of Acadia’s R&D Day will be available on the company’s website, acadia.com, under the investors section for approximately 3 months following the event.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)